labetalol has been researched along with Gestational Hypertension in 76 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose is to investigate the influence of nifedipine, labetalol, and magnesium sulfate on blood pressure control, blood coagulation, and maternal and infant outcome in those suffering from pregnancy-induced hypertension (PIH)." | 9.51 | Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension. ( Gu, S; Shao, Y; Zhang, X, 2022) |
| "To compare oral nifedipine and intravenous labetalol in the treatment of acute severe hypertension in pregnancy (SHP)." | 9.41 | Oral nifedipine may be a preferential option for treating acute severe hypertension during pregnancy: a meta-analysis. ( Cui, S; Ou, M; Yu, Y; Zhang, F; Zhao, S, 2023) |
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 9.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "To compare the change in cerebral perfusion pressure before and after intravenous labetalol vs oral nifedipine in the setting of acute severe hypertension in pregnancy." | 9.34 | Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: effects on cerebral perfusion pressure. ( Belfort, MA; Clark, SL; Fox, KA; Sangi-Haghpeykar, H; Tolcher, MC, 2020) |
| "To compare the efficacy of intravenous labetalol with oral nifedipine in the treatment of severe hypertension in pregnancy with blood pressure ≥160/110 mm Hg." | 9.30 | IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy-A randomized controlled trial. ( Sowjanya, R; Tatapudi, R; Zulfeen, M, 2019) |
| "These findings demonstrated the superiority of oral nifedipine 50,60,90 mg, especially oral nifedipine 50 mg tablets, in the treatment of severe hypertension during pregnancy than IV labetalol 300 mg, while oral nifedipine 60,90 mg also showed superiority in the successful treatment rate of severe hypertension during pregnancy than IV hydralazine 15,25 mg." | 9.22 | Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials. ( Cheng, Y; Jiang, YF; Li, JB; Wu, HZ; Yu, D; Zhu, ZN, 2022) |
| " Methyldopa, labetalol, and nifedipine have been perceived safe to use during pregnancy and are therefore recommended in international guidelines for treatment of hypertension." | 9.22 | Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. ( Allegaert, K; Flint, RB; Mian, P; Schoenmakers, S; van de Vusse, D; Versmissen, J; Visser, W, 2022) |
| "To compare pregnancy outcomes, accounting for allocated group, between methyldopa-treated and labetalol-treated women in the CHIPS Trial (ISRCTN 71416914) of 'less tight' versus 'tight' control of pregnancy hypertension." | 9.22 | Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. ( Asztalos, E; Gafni, A; Ganzevoort, JW; Gruslin, A; Helewa, M; Hutton, E; Koren, G; Lee, SK; Lee, T; Logan, AG; Magee, LA; Menzies, J; Moutquin, JM; Murphy, KE; Rey, E; Ross, S; Sanchez, J; Singer, J; Thornton, JG; von Dadelszen, P; Welch, R, 2016) |
| "To compare the effectiveness of orally administered nifedipine and intravenously administered labetalol for acute blood pressure control in hypertensive emergency of pregnancy." | 9.17 | Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. ( Sharma, C; Shekhar, S; Thakur, S; Verma, S, 2013) |
| "Oral nifedipine and intravenous labetalol regimens are similarly effective in the acute control of severe hypertension in pregnancy." | 9.16 | Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. ( Omar, SZ; Raheem, IA; Saaid, R; Tan, PC, 2012) |
| "A total of 150 consecutive pregnant women without proteinuria and with physician-recorded systolic BP of 140-160 mmHg and/or diastolic BP of 90-105 mmHg on two occasions ≥6 h apart between 20 and 38 weeks of gestation were randomly allocated to receive either labetalol or methyldopa (50 patients each) plus standard care (treatment group) or only standard care (50 patients) (control group)." | 9.16 | Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. ( Jabeen, F; Malik, AR; Mir, S; Molvi, SN; Rana, VS, 2012) |
| "To evaluate the antihypertensive efficacy of L-arginine (L-Arg) repeated infusions in women affected by gestational hypertension." | 9.12 | Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial. ( Blasi, I; Facchinetti, F; Gori, GF; Jasonni, VM; Neri, I, 2006) |
| "To determine the efficacy and safety of oral nifedipine for treatment of severe hypertension of pregnancy compared with intravenous labetalol." | 8.93 | Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. ( Gupta, N; Kirubakaran, R; Pareek, P; Shekhar, S, 2016) |
| "Labetalol is one of the most commonly used antihypertensive medications for the treatment of hypertension during pregnancy, an increasingly common and leading cause of maternal mortality and morbidity worldwide." | 8.91 | Labetalol for hypertension in pregnancy. ( Cao, V; Koren, G; Magee, LA; Namouz-Haddad, S; von Dadelszen, P, 2015) |
| "The aim of this study was to explore the hemodynamic changes of magnesium sulfate combined with labetalol in the treatment of pregnancy-induced hypertension (PIH) under Doppler uterine ultrasound based on the empirical wavelet transform (EWT) algorithm." | 8.12 | Uterine Ultrasound Doppler Hemodynamics of Magnesium Sulfate Combined with Labetalol in the Treatment of Pregnancy-Induced Hypertension Using Empirical Wavelet Transform Algorithm. ( Liu, C; Wang, F; Yin, X, 2022) |
| "To assess whether readmission for hypertension by 6 weeks postpartum differed between patients discharged on nifedipine or labetalol." | 8.12 | Postpartum Readmission for Hypertension After Discharge on Labetalol or Nifedipine. ( Do, SC; Druzin, ML; El-Sayed, YY; Girsen, AI; Herrero, T; Kan, P; Leonard, SA; Lyell, DJ; Panelli, DM, 2022) |
| "The study was performed to assess the response & side effects of injectable Labetalol in the treatment of pregnancy induced severe hypertension." | 7.85 | Response & Side Effects of Injectable Labetalol in Pregnancy Induced Severe Hypertension. ( Ahmed, MU; Akter, FA; Alom, M; Begum, F; Biswas, D; Ferdousi, RA; Hossain, MZ; Nahar, K; Rahman, MM; Razi, RZ, 2017) |
| "Compared with methyldopa, the use of labetalol for chronic hypertension of pregnancy may be associated with increased rate of hospitalization during infancy." | 7.80 | Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2014) |
| " weeks of pregnancy, were identified as significantly influencing oral clearance (CL/F) of labetalol, with CL/F ranging from 1." | 7.80 | Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. ( Deyo, K; Endres, L; Fischer, JH; Fischer, PA; Geller, S; Hardman, J; Jenkins, TM; Jeong, H; Kilpatrick, SJ; Rodvold, KA; Sarto, GE, 2014) |
| "The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase." | 7.79 | Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2013) |
| "Antihypertensive therapy in pregnancy with Labetalol may have the potential to impair fetal behavior in low degrees hypertensive diseases of pregnancy." | 7.78 | Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. ( Battistoni, GI; Bezzeccheri, V; Cecchi, L; Cecchi, S; Giannubilo, SR; Landi, B; Tranquilli, AL; Vitali, P, 2012) |
| "Response to acute treatment of severe hypertension during pregnancy in Asian women was not known." | 5.56 | Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women. ( Chera-Aree, P; Leetheeragul, J; Sampaojarean, U; Surasereewong, S; Tengtrakulcharoen, P; Wataganara, T, 2020) |
| "The purpose is to investigate the influence of nifedipine, labetalol, and magnesium sulfate on blood pressure control, blood coagulation, and maternal and infant outcome in those suffering from pregnancy-induced hypertension (PIH)." | 5.51 | Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension. ( Gu, S; Shao, Y; Zhang, X, 2022) |
| "To compare oral nifedipine and intravenous labetalol in the treatment of acute severe hypertension in pregnancy (SHP)." | 5.41 | Oral nifedipine may be a preferential option for treating acute severe hypertension during pregnancy: a meta-analysis. ( Cui, S; Ou, M; Yu, Y; Zhang, F; Zhao, S, 2023) |
| "This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines." | 5.34 | Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. ( Wang, F; Xiang, X; Zhao, N; Zhou, Z, 2020) |
| "To compare the change in cerebral perfusion pressure before and after intravenous labetalol vs oral nifedipine in the setting of acute severe hypertension in pregnancy." | 5.34 | Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: effects on cerebral perfusion pressure. ( Belfort, MA; Clark, SL; Fox, KA; Sangi-Haghpeykar, H; Tolcher, MC, 2020) |
| "The use of labetalol and nifedipine were not related to any significant changes in maternal Doppler, which is reassuring about the safety of these drugs when treating acute severe hypertension in pregnancy." | 5.34 | To study the changes in maternal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension. ( Gainder, S; Prakash, M; Saha, SC; Thakur, M, 2020) |
| "To compare the efficacy of intravenous labetalol with oral nifedipine in the treatment of severe hypertension in pregnancy with blood pressure ≥160/110 mm Hg." | 5.30 | IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy-A randomized controlled trial. ( Sowjanya, R; Tatapudi, R; Zulfeen, M, 2019) |
| " Methyldopa, labetalol, and nifedipine have been perceived safe to use during pregnancy and are therefore recommended in international guidelines for treatment of hypertension." | 5.22 | Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review. ( Allegaert, K; Flint, RB; Mian, P; Schoenmakers, S; van de Vusse, D; Versmissen, J; Visser, W, 2022) |
| " In the setting of hypertensive disorders of pregnancy, oral antihypertensive medications should be initiated when systolic blood pressure is greater than 160 mm Hg or when diastolic blood pressure is greater than 110 mm Hg, with the most ideal agents being labetalol or nifedipine." | 5.22 | Hypertensive Disorders of Pregnancy: Common Clinical Conundrums. ( Dotters-Katz, S; Kuller, JA; Lim, SL; Ohamadike, O; Siegel, A; Zemtsov, G, 2022) |
| "These findings demonstrated the superiority of oral nifedipine 50,60,90 mg, especially oral nifedipine 50 mg tablets, in the treatment of severe hypertension during pregnancy than IV labetalol 300 mg, while oral nifedipine 60,90 mg also showed superiority in the successful treatment rate of severe hypertension during pregnancy than IV hydralazine 15,25 mg." | 5.22 | Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials. ( Cheng, Y; Jiang, YF; Li, JB; Wu, HZ; Yu, D; Zhu, ZN, 2022) |
| "In summary, all commonly prescribed antihypertensives in pregnancy reduce the risk of severe hypertension, but labetalol may also decrease proteinuria/preeclampsia and fetal/newborn death." | 5.22 | Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses. ( Abalos, ED; Bone, JN; Khalil, A; Magee, LA; Omar, S; Prasad, S; Sandhu, A; Singer, J; Vidler, M; von Dadelszen, P, 2022) |
| "To compare pregnancy outcomes, accounting for allocated group, between methyldopa-treated and labetalol-treated women in the CHIPS Trial (ISRCTN 71416914) of 'less tight' versus 'tight' control of pregnancy hypertension." | 5.22 | Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. ( Asztalos, E; Gafni, A; Ganzevoort, JW; Gruslin, A; Helewa, M; Hutton, E; Koren, G; Lee, SK; Lee, T; Logan, AG; Magee, LA; Menzies, J; Moutquin, JM; Murphy, KE; Rey, E; Ross, S; Sanchez, J; Singer, J; Thornton, JG; von Dadelszen, P; Welch, R, 2016) |
| "To compare the effectiveness of orally administered nifedipine and intravenously administered labetalol for acute blood pressure control in hypertensive emergency of pregnancy." | 5.17 | Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. ( Sharma, C; Shekhar, S; Thakur, S; Verma, S, 2013) |
| "A total of 150 consecutive pregnant women without proteinuria and with physician-recorded systolic BP of 140-160 mmHg and/or diastolic BP of 90-105 mmHg on two occasions ≥6 h apart between 20 and 38 weeks of gestation were randomly allocated to receive either labetalol or methyldopa (50 patients each) plus standard care (treatment group) or only standard care (50 patients) (control group)." | 5.16 | Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. ( Jabeen, F; Malik, AR; Mir, S; Molvi, SN; Rana, VS, 2012) |
| "Oral nifedipine and intravenous labetalol regimens are similarly effective in the acute control of severe hypertension in pregnancy." | 5.16 | Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. ( Omar, SZ; Raheem, IA; Saaid, R; Tan, PC, 2012) |
| "Thirty hypertensive women during the last trimester of pregnancy were divided into four groups: non-diabetic and diabetic women treated with intravenous or oral labetalol." | 5.15 | Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients. ( Antunes, NJ; Carvalho, TM; Cavalli, Rde C; Cunha, SP; de Baraldi, CO; Godoy, AL; Lanchote, VL; Marques, MP, 2011) |
| "This review (1) summarizes currently recommended medications and dosing strategies for non-emergent HDP treatment, (2) reviews and synthesizes existing literature identified via a comprehensive PubMed search evaluating gestational changes in the maternal pharmacokinetics of commonly prescribed HDP drugs (notably labetalol and nifedipine), and (3) offers insight into the metabolism and clearance mechanisms underlying altered HDP drug pharmacokinetics during pregnancy." | 5.12 | The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions. ( Daubert, MA; Fashe, MM; Garcia, JE; Lee, CR; Loop, MS; Mulrenin, IR; Urrutia, RP, 2021) |
| "To evaluate the antihypertensive efficacy of L-arginine (L-Arg) repeated infusions in women affected by gestational hypertension." | 5.12 | Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial. ( Blasi, I; Facchinetti, F; Gori, GF; Jasonni, VM; Neri, I, 2006) |
| "To determine the efficacy and safety of oral nifedipine for treatment of severe hypertension of pregnancy compared with intravenous labetalol." | 4.93 | Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. ( Gupta, N; Kirubakaran, R; Pareek, P; Shekhar, S, 2016) |
| "Labetalol is one of the most commonly used antihypertensive medications for the treatment of hypertension during pregnancy, an increasingly common and leading cause of maternal mortality and morbidity worldwide." | 4.91 | Labetalol for hypertension in pregnancy. ( Cao, V; Koren, G; Magee, LA; Namouz-Haddad, S; von Dadelszen, P, 2015) |
| "Oral nifedipine, and possibly labetalol and methyldopa, are suitable options for treatment of severe hypertension in pregnancy/postpartum." | 4.90 | Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. ( Firoz, T; Gordon, R; MacDonell, K; Magee, LA; Payne, BA; Vidler, M; von Dadelszen, P, 2014) |
| "To assess whether readmission for hypertension by 6 weeks postpartum differed between patients discharged on nifedipine or labetalol." | 4.12 | Postpartum Readmission for Hypertension After Discharge on Labetalol or Nifedipine. ( Do, SC; Druzin, ML; El-Sayed, YY; Girsen, AI; Herrero, T; Kan, P; Leonard, SA; Lyell, DJ; Panelli, DM, 2022) |
| "The aim of this study was to explore the hemodynamic changes of magnesium sulfate combined with labetalol in the treatment of pregnancy-induced hypertension (PIH) under Doppler uterine ultrasound based on the empirical wavelet transform (EWT) algorithm." | 4.12 | Uterine Ultrasound Doppler Hemodynamics of Magnesium Sulfate Combined with Labetalol in the Treatment of Pregnancy-Induced Hypertension Using Empirical Wavelet Transform Algorithm. ( Liu, C; Wang, F; Yin, X, 2022) |
| " The American College of Obstetricians and Gynecologists recommends that acute-onset, severe hypertension be treated with first line-therapy (intravenous labetalol, intravenous hydralazine or oral nifedipine) within 60 minutes to reduce risk of maternal morbidity and death." | 3.96 | Identification of factors associated with delayed treatment of obstetric hypertensive emergencies. ( Akerman, MB; Elsayad, A; Halpern, TA; Heiselman, CJ; Heo, HJ; Kantorowska, A; Muscat, JC; Sicuranza, GB; Vintzileos, AM, 2020) |
| "The study was performed to assess the response & side effects of injectable Labetalol in the treatment of pregnancy induced severe hypertension." | 3.85 | Response & Side Effects of Injectable Labetalol in Pregnancy Induced Severe Hypertension. ( Ahmed, MU; Akter, FA; Alom, M; Begum, F; Biswas, D; Ferdousi, RA; Hossain, MZ; Nahar, K; Rahman, MM; Razi, RZ, 2017) |
| "To determine whether the incidence of hypotension or adverse fetal heart tracing (FHT) category change differed following antepartum administration of intravenous (IV) labetalol versus hydralazine." | 3.83 | Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low. ( Aghajanian, P; Greene, N; Kilpatrick, SJ; Rodriguez, M; Sharma, KJ, 2016) |
| "Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia." | 3.83 | Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. ( Bateman, BT; Desai, RJ; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Maeda, A; Mogun, H; Patorno, E; Seely, EW, 2016) |
| " weeks of pregnancy, were identified as significantly influencing oral clearance (CL/F) of labetalol, with CL/F ranging from 1." | 3.80 | Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. ( Deyo, K; Endres, L; Fischer, JH; Fischer, PA; Geller, S; Hardman, J; Jenkins, TM; Jeong, H; Kilpatrick, SJ; Rodvold, KA; Sarto, GE, 2014) |
| "Compared with methyldopa, the use of labetalol for chronic hypertension of pregnancy may be associated with increased rate of hospitalization during infancy." | 3.80 | Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2014) |
| "The use of antihypertensive drugs in pregnancy is relatively common and is increasing, with the liberal use of methyldopa and (especially) labetalol contributing appreciably to this increase." | 3.79 | Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. ( Guo, Y; Krewski, D; Mattison, D; Nerenberg, K; Walker, MC; Wen, SW; Xie, RH, 2013) |
| "Nine mothers were treated with labetalol and/or MgSO4 during pregnancy, three mothers with labetalol, MgSO4 and nifedipine, and 19 mothers with nifedipine only." | 3.79 | Maternal antihypertensive drugs may influence cerebral oxygen extraction in preterm infants during the first days after birth. ( Bos, AF; Kooi, EM; van den Berg, PP; Verhagen, EA, 2013) |
| "Antihypertensive therapy in pregnancy with Labetalol may have the potential to impair fetal behavior in low degrees hypertensive diseases of pregnancy." | 3.78 | Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. ( Battistoni, GI; Bezzeccheri, V; Cecchi, L; Cecchi, S; Giannubilo, SR; Landi, B; Tranquilli, AL; Vitali, P, 2012) |
| "Labetalol is commonly used for control of hypertension in pregnancy." | 3.77 | False-positive amphetamine toxicology screen results in three pregnant women using labetalol. ( Wu, D; Yee, LM, 2011) |
| "Live-born children born in these hospitals and prenatally exposed to labetalol, methyldopa, or bed rest because of mild-to-moderate gestational hypertension." | 3.76 | Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study. ( Eskes, TK; Gabreëls, FJ; Pasker-de Jong, PC; Pellegrino, A; van Gelder, MM; Zielhuis, GA, 2010) |
| "Hypertension during pregnancy is associated with a higher risk of cardiovascular disease and kidney failure." | 3.01 | Evaluation and Management of Hypertensive Disorders of Pregnancy. ( Bajpai, D; Dumanski, S; Popa, C; Shah, S; Verma, P, 2023) |
| "Pregnancy-induced hypertension is a major cause of maternal and fetal morbidity and mortality." | 2.61 | Hypertension and Pregnancy: Management and Future Risks. ( Jim, B; Reddy, S, 2019) |
| "Women with chronic hypertension are at significant risk for maternal and fetal morbidity and mortality, yet it remains unclear whether antihypertensive treatment during pregnancy lowers these risks." | 2.55 | New Evidence in the Management of Chronic Hypertension in Pregnancy. ( August, P; Podymow, T, 2017) |
| "The HDP spectrum includes gestational hypertension (HTN), preeclampsia, eclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome, chronic HTN, and chronic HTN with superimposed preeclampsia." | 1.72 | Hypertensive Conditions: Hypertensive Disorders in Pregnancy. ( Daly, PL; Goodwin, ET; Kipnis, CM; Smith, DK, 2022) |
| "Response to acute treatment of severe hypertension during pregnancy in Asian women was not known." | 1.56 | Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women. ( Chera-Aree, P; Leetheeragul, J; Sampaojarean, U; Surasereewong, S; Tengtrakulcharoen, P; Wataganara, T, 2020) |
| "Labetalol was the commonest antihypertensive used." | 1.43 | Survey of healthcare professionals regarding adjustment of antihypertensive medication(s) in the postnatal period in women with hypertensive disorders of pregnancy. ( Cairns, AE; Leeson, P; Mackillop, L; McManus, RJ; Tucker, KL, 2016) |
| "During hypoxemia, fetal heart rate increased to baseline in the pindolol group and pulmonary vascular impedances increased in the labetalol group, with no changes in fetal cardiac outputs." | 1.39 | Fetal cardiac function after labetalol or pindolol for maternal hypertension in a sheep model of increased placental vascular resistance. ( Acharya, G; Erkinaro, T; Haapsamo, M; Kavasmaa, T; Mäkikallio, K; Räsänen, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (6.58) | 29.6817 |
| 2010's | 45 (59.21) | 24.3611 |
| 2020's | 26 (34.21) | 2.80 |
| Authors | Studies |
|---|---|
| Mulrenin, IR | 1 |
| Garcia, JE | 1 |
| Fashe, MM | 1 |
| Loop, MS | 1 |
| Daubert, MA | 1 |
| Urrutia, RP | 1 |
| Lee, CR | 1 |
| Ashworth, D | 1 |
| Battersby, C | 1 |
| Green, M | 1 |
| Hardy, P | 1 |
| McManus, RJ | 3 |
| Cluver, C | 1 |
| Chappell, LC | 3 |
| Bone, JN | 1 |
| Sandhu, A | 1 |
| Abalos, ED | 1 |
| Khalil, A | 1 |
| Singer, J | 5 |
| Prasad, S | 1 |
| Omar, S | 1 |
| Vidler, M | 2 |
| von Dadelszen, P | 8 |
| Magee, LA | 9 |
| Wu, HZ | 1 |
| Cheng, Y | 1 |
| Yu, D | 1 |
| Li, JB | 1 |
| Jiang, YF | 1 |
| Zhu, ZN | 1 |
| Ohamadike, O | 1 |
| Lim, SL | 1 |
| Siegel, A | 1 |
| Zemtsov, G | 1 |
| Kuller, JA | 1 |
| Dotters-Katz, S | 1 |
| Dublin, S | 1 |
| Idu, A | 1 |
| Avalos, LA | 1 |
| Cheetham, TC | 1 |
| Easterling, TR | 1 |
| Chen, L | 2 |
| Holt, VL | 1 |
| Nance, N | 1 |
| Bider-Canfield, Z | 1 |
| Neugebauer, RS | 1 |
| Reynolds, K | 1 |
| Badon, SE | 1 |
| Shortreed, SM | 1 |
| Liu, C | 1 |
| Wang, F | 2 |
| Yin, X | 1 |
| Do, SC | 1 |
| Leonard, SA | 1 |
| Kan, P | 1 |
| Panelli, DM | 1 |
| Girsen, AI | 1 |
| Lyell, DJ | 1 |
| El-Sayed, YY | 1 |
| Druzin, ML | 1 |
| Herrero, T | 1 |
| van de Vusse, D | 1 |
| Mian, P | 1 |
| Schoenmakers, S | 1 |
| Flint, RB | 1 |
| Visser, W | 1 |
| Allegaert, K | 1 |
| Versmissen, J | 1 |
| Shao, Y | 1 |
| Gu, S | 1 |
| Zhang, X | 1 |
| Kipnis, CM | 1 |
| Daly, PL | 1 |
| Goodwin, ET | 1 |
| Smith, DK | 1 |
| Trahan, MJ | 1 |
| Plourde, M | 1 |
| Wou, K | 1 |
| Huroy, M | 1 |
| Itani, R | 1 |
| Pavilanis, A | 1 |
| Flannery, A | 1 |
| Haas, S | 1 |
| Aucoin, G | 1 |
| Monast, PO | 1 |
| Koolian, M | 1 |
| Hassan, N | 1 |
| Suarthana, E | 1 |
| Daskalopoulou, SS | 1 |
| Malhamé, I | 1 |
| Kou, X | 1 |
| Yang, J | 1 |
| Wasif, U | 1 |
| Al-Shehab, U | 1 |
| Lo, DF | 1 |
| Cífková, R | 1 |
| Ou, M | 1 |
| Zhang, F | 1 |
| Cui, S | 1 |
| Zhao, S | 1 |
| Yu, Y | 1 |
| Bajpai, D | 1 |
| Popa, C | 1 |
| Verma, P | 1 |
| Dumanski, S | 1 |
| Shah, S | 1 |
| Rey, E | 4 |
| Asztalos, E | 3 |
| Hutton, E | 3 |
| Helewa, M | 3 |
| Lee, T | 4 |
| Logan, AG | 4 |
| Ganzevoort, W | 1 |
| Welch, R | 3 |
| Thornton, JG | 3 |
| Lay-Flurrie, S | 1 |
| Myers, J | 1 |
| Kantorowska, A | 1 |
| Heiselman, CJ | 1 |
| Halpern, TA | 1 |
| Akerman, MB | 1 |
| Elsayad, A | 1 |
| Muscat, JC | 1 |
| Sicuranza, GB | 1 |
| Vintzileos, AM | 1 |
| Heo, HJ | 1 |
| Tolcher, MC | 1 |
| Fox, KA | 1 |
| Sangi-Haghpeykar, H | 1 |
| Clark, SL | 1 |
| Belfort, MA | 1 |
| Thakur, M | 1 |
| Gainder, S | 1 |
| Saha, SC | 1 |
| Prakash, M | 1 |
| Chera-Aree, P | 1 |
| Tengtrakulcharoen, P | 1 |
| Leetheeragul, J | 1 |
| Sampaojarean, U | 1 |
| Surasereewong, S | 1 |
| Wataganara, T | 1 |
| Martin, C | 1 |
| Pappas, J | 1 |
| Johns, K | 1 |
| Figueroa, H | 1 |
| Balli, K | 1 |
| Yao, R | 1 |
| Yoon, SW | 1 |
| Choi, GJ | 1 |
| Seong, HK | 1 |
| Lee, MJ | 1 |
| Kang, H | 1 |
| Xiang, X | 1 |
| Zhao, N | 1 |
| Zhou, Z | 1 |
| Mullan, SJ | 1 |
| Vricella, LK | 1 |
| Edwards, AM | 1 |
| Powel, JE | 1 |
| Ong, SK | 1 |
| Li, X | 1 |
| Tomlinson, TM | 1 |
| Sharma, KJ | 2 |
| Kilpatrick, SJ | 4 |
| Fitton, CA | 1 |
| Steiner, MFC | 1 |
| Aucott, L | 1 |
| Pell, JP | 1 |
| Mackay, DF | 1 |
| Fleming, M | 1 |
| McLay, JS | 1 |
| Podymow, T | 1 |
| August, P | 1 |
| Akter, FA | 1 |
| Nahar, K | 1 |
| Rahman, MM | 1 |
| Ferdousi, RA | 1 |
| Ahmed, MU | 1 |
| Begum, F | 1 |
| Biswas, D | 1 |
| Alom, M | 1 |
| Hossain, MZ | 1 |
| Razi, RZ | 1 |
| Wang, Y | 1 |
| Shi, D | 1 |
| Shawkat, E | 1 |
| Mistry, H | 1 |
| Chmiel, C | 1 |
| Webster, L | 1 |
| Chappell, L | 1 |
| Johnstone, ED | 1 |
| Myers, JE | 1 |
| Webster, LM | 1 |
| Webb, AJ | 1 |
| Zulfeen, M | 1 |
| Tatapudi, R | 1 |
| Sowjanya, R | 1 |
| Reddy, S | 1 |
| Jim, B | 1 |
| Easterling, T | 1 |
| Mundle, S | 1 |
| Bracken, H | 1 |
| Parvekar, S | 1 |
| Mool, S | 1 |
| Shochet, T | 1 |
| Winikoff, B | 1 |
| Arulkumaran, N | 1 |
| Lightstone, L | 1 |
| Shekhar, S | 2 |
| Sharma, C | 1 |
| Thakur, S | 1 |
| Verma, S | 1 |
| Xie, RH | 2 |
| Guo, Y | 2 |
| Krewski, D | 2 |
| Mattison, D | 2 |
| Nerenberg, K | 2 |
| Walker, MC | 2 |
| Wen, SW | 2 |
| Fischer, JH | 1 |
| Sarto, GE | 1 |
| Hardman, J | 1 |
| Endres, L | 1 |
| Jenkins, TM | 1 |
| Jeong, H | 1 |
| Geller, S | 1 |
| Deyo, K | 1 |
| Fischer, PA | 1 |
| Rodvold, KA | 1 |
| Firoz, T | 1 |
| MacDonell, K | 1 |
| Payne, BA | 1 |
| Gordon, R | 1 |
| Vadhera, RB | 1 |
| Simon, M | 1 |
| Morris, R | 1 |
| Sunesara, I | 1 |
| Darby, M | 1 |
| Novotny, S | 1 |
| Kiprono, L | 1 |
| Bautista, L | 1 |
| Sawardecker, S | 1 |
| Bofill, J | 1 |
| Anderson, B | 1 |
| Martin, JN | 1 |
| Namouz-Haddad, S | 1 |
| Cao, V | 1 |
| Koren, G | 3 |
| Gómez Torrijos, E | 1 |
| García Rodríguez, C | 1 |
| Sánchez Caminero, MP | 1 |
| Castro Jiménez, A | 1 |
| García Rodríguez, R | 1 |
| Feo-Brito, F | 1 |
| Gupta, N | 1 |
| Kirubakaran, R | 1 |
| Pareek, P | 1 |
| Ross, S | 2 |
| Murphy, KE | 2 |
| Menzies, J | 2 |
| Sanchez, J | 2 |
| Gafni, A | 2 |
| Gruslin, A | 2 |
| Lee, SK | 2 |
| Ganzevoort, JW | 2 |
| Moutquin, JM | 2 |
| Clark, SM | 1 |
| Dunn, HE | 1 |
| Hankins, GD | 1 |
| Olson-Chen, C | 1 |
| Seligman, NS | 1 |
| Abreo, A | 1 |
| Greene, N | 2 |
| Melsop, K | 1 |
| Peterson, N | 1 |
| Shields, LE | 1 |
| Main, EK | 1 |
| Rodriguez, M | 1 |
| Aghajanian, P | 1 |
| Thewissen, L | 1 |
| Pistorius, L | 1 |
| Baerts, W | 1 |
| Naulaers, G | 1 |
| Van Bel, F | 1 |
| Lemmers, P | 1 |
| Stott, D | 1 |
| Bolten, M | 1 |
| Salman, M | 1 |
| Paraschiv, D | 1 |
| Douiri, A | 1 |
| Kametas, NA | 1 |
| Bateman, BT | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Seely, EW | 1 |
| Mogun, H | 1 |
| Maeda, A | 1 |
| Fischer, MA | 1 |
| Hernandez-Diaz, S | 1 |
| Huybrechts, KF | 1 |
| Cairns, AE | 1 |
| Tucker, KL | 1 |
| Leeson, P | 1 |
| Mackillop, L | 1 |
| Pasker-de Jong, PC | 1 |
| Zielhuis, GA | 1 |
| van Gelder, MM | 1 |
| Pellegrino, A | 1 |
| Gabreëls, FJ | 1 |
| Eskes, TK | 1 |
| Carvalho, TM | 1 |
| Cavalli, Rde C | 1 |
| Cunha, SP | 1 |
| de Baraldi, CO | 1 |
| Marques, MP | 1 |
| Antunes, NJ | 1 |
| Godoy, AL | 1 |
| Lanchote, VL | 1 |
| Graham, DF | 1 |
| Hadlow, N | 1 |
| Tsokos, N | 1 |
| Oates, R | 1 |
| Yee, LM | 1 |
| Wu, D | 1 |
| Ciantar, E | 1 |
| Walker, JJ | 1 |
| Koucký, M | 1 |
| Raheem, IA | 1 |
| Saaid, R | 1 |
| Omar, SZ | 1 |
| Tan, PC | 1 |
| Molvi, SN | 1 |
| Mir, S | 1 |
| Rana, VS | 1 |
| Jabeen, F | 1 |
| Malik, AR | 1 |
| Giannubilo, SR | 1 |
| Bezzeccheri, V | 1 |
| Cecchi, S | 1 |
| Landi, B | 1 |
| Battistoni, GI | 1 |
| Vitali, P | 1 |
| Cecchi, L | 1 |
| Tranquilli, AL | 1 |
| Erkinaro, T | 1 |
| Haapsamo, M | 1 |
| Kavasmaa, T | 1 |
| Mäkikallio, K | 1 |
| Acharya, G | 1 |
| Räsänen, J | 1 |
| Verhagen, EA | 1 |
| Kooi, EM | 1 |
| van den Berg, PP | 1 |
| Bos, AF | 1 |
| Mansour, G | 1 |
| Mansour, J | 1 |
| Patel, N | 1 |
| Riordan-Eva, P | 1 |
| Chong, V | 1 |
| Heazell, AE | 1 |
| Mahomoud, S | 1 |
| Pirie, AM | 1 |
| Neri, I | 1 |
| Jasonni, VM | 1 |
| Gori, GF | 1 |
| Blasi, I | 1 |
| Facchinetti, F | 1 |
| Vigil-De Gracia, P | 1 |
| Ruiz, E | 1 |
| López, JC | 1 |
| de Jaramillo, IA | 1 |
| Vega-Maleck, JC | 1 |
| Pinzón, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The CHIPS Trial (Control of Hypertension In Pregnancy Study)[NCT01192412] | 987 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| Use of Meditation as a Complementary Therapy in the Treatment of Gestational Hypertension[NCT03873194] | 47 participants (Actual) | Interventional | 2019-04-15 | Completed | |||
| Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy[NCT01912677] | Phase 4 | 894 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial[NCT03262961] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pregnancy loss or NICU admission for greater than 48 hours, as recorded in the maternal and infant medical records immediately following the birth (or pregnancy loss), and then again after the mothers' and infants' discharge home. Supplemental information, about potential post-discharge maternal or neonatal morbidities in the 6 weeks following birth for the mother, or 28 days of life for the baby, will be obtained by contacting women at 6 weeks postpartum and/or from medical records. (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 155 |
| 'Tight' Control. | 150 |
"Serious maternal complications measured up to 6 weeks postpartum. Death or one or more life-threatening maternal complications:~Adverse neurological complications (stroke, eclampsia, and/or blindness), and/or~End-organ failure (uncontrolled hypertension, inotropic support, pulmonary oedema, respiratory failure, myocardial ischaemia/infarction, renal failure, coagulopathy, and/or transfusion)" (NCT01192412)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| 'Less Tight' Control. | 18 |
| 'Tight' Control. | 10 |
22 reviews available for labetalol and Gestational Hypertension
| Article | Year |
|---|---|
The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nifedipine; Pha | 2021 |
Oral Antihypertensives for Nonsevere Pregnancy Hypertension: Systematic Review, Network Meta- and Trial Sequential Analyses.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Patient | 2022 |
Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension; Hypertension, Pr | 2022 |
Hypertensive Disorders of Pregnancy: Common Clinical Conundrums.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; P | 2022 |
Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.
Topics: Antihypertensive Agents; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; M | 2022 |
Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2023 |
Oral nifedipine may be a preferential option for treating acute severe hypertension during pregnancy: a meta-analysis.
Topics: Blood Pressure; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nifedipine; Pregnancy | 2023 |
Evaluation and Management of Hypertensive Disorders of Pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; Labetalol | 2023 |
Postpartum Hypertension: Etiology, Diagnosis, and Management.
Topics: Antihypertensive Agents; Blood Pressure; Disease Management; Female; Humans; Hydralazine; Hypertensi | 2017 |
In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review.
Topics: Antihypertensive Agents; Attention Deficit Disorder with Hyperactivity; Birth Weight; Child; Child H | 2017 |
New Evidence in the Management of Chronic Hypertension in Pregnancy.
Topics: Algorithms; Antihypertensive Agents; Blood Pressure; Chronic Disease; Female; Humans; Hypertension; | 2017 |
What is the evidence for using labetalol as a first-line treatment option for hypertension in pregnancy?
Topics: Antihypertensive Agents; Evidence-Based Medicine; Female; Humans; Hypertension, Pregnancy-Induced; L | 2018 |
Hypertension and Pregnancy: Management and Future Risks.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Chronic Disease; Diuretics; Female; Human | 2019 |
Severe pre-eclampsia and hypertensive crises.
Topics: Administration, Intravenous; Administration, Oral; Antihypertensive Agents; Critical Care; Early Dia | 2013 |
Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review.
Topics: Administration, Oral; Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension, Pregnancy- | 2014 |
Hypertensive emergencies in pregnancy.
Topics: Antihypertensive Agents; Eclampsia; Emergencies; Female; Humans; Hydralazine; Hypertension; Hyperten | 2014 |
Labetalol for hypertension in pregnancy.
Topics: Antihypertensive Agents; Canada; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Practic | 2015 |
Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Cost-Benefit Anal | 2016 |
A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension, | 2015 |
Hypertensive Emergencies in Pregnancy.
Topics: Antihypertensive Agents; Cesarean Section; Chronic Disease; Congenital Abnormalities; Emergencies; E | 2016 |
Pre-eclampsia, severe pre-eclampsia and hemolysis, elevated liver enzymes and low platelets syndrome: what is new?
Topics: Anticoagulants; Antihypertensive Agents; Female; HELLP Syndrome; Heparin; Humans; Hypertension, Preg | 2011 |
[Current perspective of treating hypertension in pregnancy].
Topics: Antihypertensive Agents; Calcium Channel Blockers; Female; Humans; Hypertension; Hypertension, Pregn | 2011 |
19 trials available for labetalol and Gestational Hypertension
| Article | Year |
|---|---|
Effects of Nifedipine and Labetalol Combined with Magnesium Sulfate on Blood Pressure Control, Blood Coagulation Function, and Maternal and Infant Outcome in Patients with Pregnancy-Induced Hypertension.
Topics: Antihypertensive Agents; Blood Coagulation; Blood Pressure; Female; Humans; Hypertension; Hypertensi | 2022 |
Labetalol, Low-dose Aspirin, and Vitamin E and Calcium for Gestational Hypertension and Influence on MicroRNA-126 and PLGF Levels.
Topics: Aspirin; Calcium; Female; Humans; Hypertension; Hypertension, Pregnancy-Induced; Labetalol; MicroRNA | 2023 |
Management of non-severe pregnancy hypertension - A summary of the CHIPS Trial (Control of Hypertension in Pregnancy Study) research publications.
Topics: Adult; Antihypertensive Agents; Canada; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; | 2019 |
Are blood pressure level and variability related to pregnancy outcome? Analysis of control of hypertension in pregnancy study data.
Topics: Adult; Antihypertensive Agents; Birth Weight; Female; Humans; Hypertension; Hypertension, Pregnancy- | 2020 |
Intravenous labetalol versus oral nifedipine for acute hypertension in pregnancy: effects on cerebral perfusion pressure.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Cerebrovascular Circulation; Cohort Studies; F | 2020 |
To study the changes in maternal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; F | 2020 |
Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Aspirin; Blood Pressure; Do | 2020 |
Lipid profile and cytokines in hypertension of pregnancy: A comparison of preeclampsia therapies.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cytokines; Double-Blind Method; Drug Administration | 2018 |
IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy-A randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Antihypertensive Agents; Double-Blind Method; Fem | 2019 |
Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension, | 2019 |
Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; D | 2013 |
Impedance cardiography assessed treatment of acute severe pregnancy hypertension: a randomized trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Cardiac Output; Cardiography, Impedance; Female; Hum | 2016 |
Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?
Topics: Adult; Antihypertensive Agents; Blood Pressure; Clinical Decision-Making; Female; Humans; Hypertensi | 2016 |
Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnanc | 2016 |
Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Area Under Curve; Blood Pressure; Diabetes | 2011 |
Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Emergenci | 2012 |
Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa.
Topics: Adult; Antihypertensive Agents; Cesarean Section; Female; Humans; Hypertension, Pregnancy-Induced; I | 2012 |
Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial.
Topics: Adolescent; Adult; Antihypertensive Agents; Arginine; Blood Pressure; Female; Gestational Age; Human | 2006 |
Management of severe hypertension in the postpartum period with intravenous hydralazine or labetalol: a randomized clinical trial.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; H | 2007 |
35 other studies available for labetalol and Gestational Hypertension
| Article | Year |
|---|---|
Which antihypertensive treatment is better for mild to moderate hypertension in pregnancy?
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Methyldopa; Nif | 2022 |
Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: A retrospective cohort study.
Topics: Antihypertensive Agents; Birth Weight; Female; Humans; Hypertension, Pregnancy-Induced; Infant; Infa | 2022 |
Uterine Ultrasound Doppler Hemodynamics of Magnesium Sulfate Combined with Labetalol in the Treatment of Pregnancy-Induced Hypertension Using Empirical Wavelet Transform Algorithm.
Topics: Algorithms; Female; Hemodynamics; Humans; Hypertension, Pregnancy-Induced; Labetalol; Magnesium Sulf | 2022 |
Postpartum Readmission for Hypertension After Discharge on Labetalol or Nifedipine.
Topics: Antihypertensive Agents; Cohort Studies; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2022 |
Hypertensive Conditions: Hypertensive Disorders in Pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nifedipine; Pre | 2022 |
Identifying Targets to Improve the Management of Severe Hypertension in Pregnancy and Postpartum.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2023 |
Critical commentary on labetalol and nifedipine use in postpartum hypertension management.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pregnancy-Induc | 2023 |
Identification of factors associated with delayed treatment of obstetric hypertensive emergencies.
Topics: Administration, Intravenous; Administration, Oral; Adult; After-Hours Care; Antihypertensive Agents; | 2020 |
Clinical Experiences of Intravenous Hydralazine and Labetalol for Acute Treatment of Severe Hypertension in Pregnant Thai Women.
Topics: Administration, Intravenous; Adult; Antihypertensive Agents; Apgar Score; Asian People; Blood Pressu | 2020 |
Semiautonomous Treatment Algorithm for the Management of Severe Hypertension in Pregnancy.
Topics: Adult; Algorithms; Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetal | 2021 |
Pharmacological strategies to prevent haemodynamic changes after intubation in parturient women with hypertensive disorders of pregnancy: A network meta-analysis.
Topics: Anesthesia, General; Antihypertensive Agents; Apgar Score; Blood Pressure; Blood Pressure Determinat | 2021 |
Pulse pressure as a predictor of response to treatment for severe hypertension in pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension, Pregnancy-Induced; Infant; La | 2021 |
Response & Side Effects of Injectable Labetalol in Pregnancy Induced Severe Hypertension.
Topics: Antihypertensive Agents; Bangladesh; Blood Pressure; Female; Humans; Hypertension; Hypertension, Pre | 2017 |
The effect of labetalol and nifedipine MR on blood pressure in women with chronic hypertension in pregnancy.
Topics: Adrenergic Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Chronic D | 2018 |
Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Female; Humans; Hypertension; Hypertens | 2013 |
Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy.
Topics: Adolescent; Adult; Antihypertensive Agents; Body Weight; Dose-Response Relationship, Drug; Female; G | 2014 |
Association between labetalol use for hypertension in pregnancy and adverse infant outcomes.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Infant, Newborn; In | 2014 |
First case report of acute generalized exanthematous pustulosis due to labetalol.
Topics: Acute Generalized Exanthematous Pustulosis; Adrenergic Antagonists; Adult; Antihypertensive Agents; | 2015 |
Oral nifedipine or intravenous labetalol for severe hypertension?
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nifedipine; Pra | 2016 |
Severe maternal morbidity in a large cohort of women with acute severe intrapartum hypertension.
Topics: Adult; Antihypertensive Agents; California; Female; Humans; Hydralazine; Hypertension, Pregnancy-Ind | 2016 |
Risks of parenteral antihypertensive therapy for the treatment of severe maternal hypertension are low.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Female; Humans; Hydralazine; Hypertension, Pregnancy | 2016 |
Neonatal haemodynamic effects following foetal exposure to labetalol in hypertensive disorders of pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Case-Control Studies; Cerebrum; Female; Gestational Age; He | 2017 |
A prediction model for the response to oral labetalol for the treatment of antenatal hypertension.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Logistic | 2017 |
Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Cohort Studies; Female; Humans; Hypertension; Hy | 2016 |
Survey of healthcare professionals regarding adjustment of antihypertensive medication(s) in the postnatal period in women with hypertensive disorders of pregnancy.
Topics: Antihypertensive Agents; Blood Pressure; Female; General Practice; Guideline Adherence; Humans; Hype | 2016 |
Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study.
Topics: Antihypertensive Agents; Attention; Attention Deficit Disorder with Hyperactivity; Bed Rest; Child; | 2010 |
A case of hypertension with virilisation during pregnancy.
Topics: Adult; Aspirin; Brenner Tumor; Calcium; Cesarean Section; Dehydroepiandrosterone Sulfate; Dietary Su | 2010 |
False-positive amphetamine toxicology screen results in three pregnant women using labetalol.
Topics: Adult; Amphetamine; Antihypertensive Agents; Cesarean Section; Chronic Disease; Cocaine; Cross React | 2011 |
Committee Opinion no. 514: emergent therapy for acute-onset, severe hypertension with preeclampsia or eclampsia.
Topics: Algorithms; Antihypertensive Agents; Female; Humans; Hydralazine; Hypertension, Pregnancy-Induced; L | 2011 |
Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Female; Humans; Hypertension, Pregnancy-Induc | 2012 |
Fetal cardiac function after labetalol or pindolol for maternal hypertension in a sheep model of increased placental vascular resistance.
Topics: Animals; Antihypertensive Agents; Female; Fetal Heart; Hypertension, Pregnancy-Induced; Hypoxia; Lab | 2013 |
Maternal antihypertensive drugs may influence cerebral oxygen extraction in preterm infants during the first days after birth.
Topics: Antihypertensive Agents; Case-Control Studies; Cerebral Cortex; Cerebrovascular Circulation; Female; | 2013 |
Nicardipine or labetalol as short-term treatment for severe hypertension of pregnancy.
Topics: Antihypertensive Agents; Female; Humans; Hypertension, Pregnancy-Induced; Labetalol; Nicardipine; Pr | 2004 |
Persistent visual loss after retinochoroidal infarction in pregnancy-induced hypertension and disseminated intravascular coagulation.
Topics: Adult; Antihypertensive Agents; Blindness; Choroid; Disseminated Intravascular Coagulation; Female; | 2005 |
The treatment of severe hypertension in pregnancy: a review of current practice and knowledge in West-Midlands maternity units.
Topics: Antihypertensive Agents; Female; Hospital Units; Humans; Hydralazine; Hypertension, Pregnancy-Induce | 2004 |